Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2021)
Revolution Medicines (RVMD) posted Amortization of Deferred Charges of $979000.0 for Q4 2021, up 41.68% on a QoQ basis from $691000.0 in Q3 2021, and up 28.99% year-over-year from $759000.0 in Q4 2020.
Powered by 
Analysis
Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Revolution Medicines has reported Amortization of Deferred Charges for 2 years, with the latest figure at $979000.0 in Q4 2021.
- On a quarterly basis, Amortization of Deferred Charges rose 28.99% year-over-year to $979000.0 in Q4 2021; TTM through Dec 2021 was $3.2 million, a 10.96% increase from a year earlier, with the FY2021 full-year figure at $3.2 million, up 10.96% from the prior year.
- Amortization of Deferred Charges was $979000.0 for Q4 2021 at Revolution Medicines, up from $691000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $979000.0 in Q4 2021, with the low at $645000.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 979,000.00 |
| Sep 30, 2021 | 691,000.00 |
| Jun 30, 2021 | 770,000.00 |
| Mar 31, 2021 | 740,000.00 |
| Dec 31, 2020 | 759,000.00 |
| Sep 30, 2020 | 698,000.00 |
| Jun 30, 2020 | 764,000.00 |
| Mar 31, 2020 | 645,000.00 |